BackgroundAttention deficit hyperactivity disorder (ADHD) is a disorder characterized by hyperactive, impulsive, and/or inattentive symptoms. Adults with ADHD often report reduced quality of life (QoL) across social, educational, and occupational functioning. Part of these deficits may be attributed to stigma, which includes stereotypes, prejudices, discrimination, and negative labelling. While stigma’s effects on QoL have been extensively documented in other mental health conditions, the specific types and impacts of stigma experienced by adults with ADHD remain underexplored in recent reviews.AimsTo identify and describe the different types of stigmas experienced by adults with ADHD, while exploring how stigma may impact QoL’s key domains as defined by WHO (physical domain, psychological domain, level of independence, social relationships, environment, and spirituality/religion/personal beliefs).MethodsA literature search was conducted across APA PsycArticles, Embase, and Ovid MEDLINE(R) for ADHD AND stigma-related keywords. Eligible studies were English, peer-reviewed articles from the past decade involving adults (≥18) and describing or specifying at least one type of stigma.ResultsA total of 17 papers met the inclusion criteria. Stigma types included self-stigma and/or internalized stigma, perceived stigma, public stigma, and structural stigma. QoL domains affected included the psychological domain, social relationships, environment, and level of independence. Greater ADHD symptomatology was positively correlated with more internalized stigma, which in turn was linked to functional impairment, worse self-esteem, and poorer QoL. Self-stigma manifested as self-deprecating labels and ADHD devaluation. Perceived stigma hindered treatment seeking, medication compliance, and diagnostic disclosure, although associations with QoL were insignificant. Public stigma was the most investigated and related to negative societal attitudes, notably in academic contexts. Few studies looked at structural stigma; those that did identified structural barriers to care, though none directly assessed QoL outcomes.ConclusionStigma remains pervasive, though direct effects on QoL domains are less widely investigated. Future studies should investigate structural stigma in more depth and explore causal relationships between stigma and QoL.Systematic Review Registrationhttps://doi.org/10.17605/OSF.IO/Y52HK
Tuning the immune response to mRNA vaccines
Nature Biotechnology, Published online: 29 April 2026; doi:10.1038/s41587-026-03125-0
A strategy to control translation of mRNA vaccines reveals cell type–specific contributions to immunity that may be harnessed to enhance vaccine efficacy.
mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression
Nature Biotechnology, Published online: 29 April 2026; doi:10.1038/s41587-026-03099-z
mRNA vaccine efficacy is enhanced by silencing cell-type-specific expression.
Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia
Nature Medicine, Published online: 29 April 2026; doi:10.1038/s41591-026-04338-1
A multicountry cohort study found that prediction models combining clinical parameters with either pulse oximetry or the host biomarker sTREM1 more accurately identified febrile children needing referral than standard WHO criteria.
Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial
Nature Medicine, Published online: 29 April 2026; doi:10.1038/s41591-026-04366-x
Preclinical and phase 1/2 trial data show that anti-CD38 monoclonal antibody treatment restores platelet counts in patients with immune thrombocytopenia by increasing nicotinamide adenine dinucleotide (NAD+) levels, and low-dose oral treatment with the NAD+ precursor nicotinamide mononucleotide can similarly increase platelet counts without serious adverse effects.
An agentic framework for autonomous scientific discovery in cancer pathology
Nature Medicine, Published online: 29 April 2026; doi:10.1038/s41591-026-04357-y
Evaluated across 18 multicancer cohorts, the agentic artificial intelligence workflow SPARK uses language as a universal interface to autonomously generate biological ideas.
A septo–entorhinal GABAergic pathway that enables switching between episodic memories
Nature Neuroscience, Published online: 29 April 2026; doi:10.1038/s41593-026-02280-6
How the brain organizes the retrieval of old and new memories remains unknown. Kim et al. identify a septo−entorhinal GABAergic pathway that controls flexible switching between episodic memories during memory retrieval to enable memory updating.
Food safety experts warn of USDA brain drain
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Morning. In the same way that Athena orchestrated the logistics around Telemachus’s journey in the first three books of “The Odyssey,” I hope some gods out there are coordinating a “Survivor” season 50 win for Cirie Fields. She’s earning it, but I wouldn’t mind some divine intervention to make sure.
Opinion: The medical school nutrition blues
One of health secretary Robert F. Kennedy’s refrains has focused on medical education: Doctors don’t know enough about nutrition and preventive medicine, he likes to say. He has encouraged medical schools to beef up (tallow up?) their education on healthy eating and its connection to chronic disease.
What do medical students think of this?
Opinion: STAT+: Did Kennedy just stack the deck on FDA oversight of peptides?
I’ve been waiting for health secretary Robert F. Kennedy Jr. to do something big on oversight of what I call pop peptides, like BPC-157 and GHK-Cu. He had long signaled that he was going to free such peptides from what he saw as a past, misguided FDA that had banned them in 2023.
It’s finally happened — and the way it went down shook me up a bit.
For a few years, a loophole in compounding rules had allowed specialty pharmacies to make and market these peptides. It effectively meant that substances nominated for compounding — even unproven drugs — could be made and marketed by qualified pharmacies while the FDA pondered the nominations. But in 2023, the Food and Drug Administration rightly moved peptides to a no-compounding-allowed status called Category 2 due to concerns about safety and lack of clinical trial data. Now Kennedy is working to undo that with major risks to the public.